الخميس 10 محرم 1448هـ
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
| عنوان الدراسة | داعم الدراسة | حالة الدراسة | دواء الدراسة | مرحلة الدراسة | رقم بروتوكول الدراسة | موقع الدراسة |
|---|---|---|---|---|---|---|
| An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I) | AbbVie | Ongoing | ABT-450/r/ABT-267 ABT-333Ribavirin (RBV) | 3b | M14-423 | King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Jeddah), King Fahad Hospital (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Multicenter, Open-label, Single-arm Study of a Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2- Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer | Roche | Ongoing | Pertuzumab / Trastuzumab / Taxane | 3b | MO28047 | King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah) |
| The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias | ApoPharma Inc. | Ongoing | Deferiprone Deferoxamine | 3b | LA38-0411 | Aseer Central Hospital, King Abdulaziz University Hospital (Jeddah), King Khalid University Hospital (Riyadh) |
| Risk assesment and mangement of Vte in women at risk of thromboEmbolism during pregnancy and puerperium | Sanofi | Ongoing | N/A | 4 | OBS14159 | King Abdulaziz University Hospital (Jeddah) |
| A PHASE III PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE EARLY BREAST CANCER [SafeHer Study] | Roche | Ongoing | trastuzumab | 3 | MO28048 | King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Riyadh) |
| A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) | MSD | Ongoing | (Sitagliptin / Metformin) | 3 | MK0431-170 | King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Hospital NG (Al Ahsa) |
| A Phase III Multicenter, Double-Blind, Randomized, Placebo- Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-Dose Combination Tablet of Sitagliptin and Extended-Release Metformin) in Pediatric Subjects with Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy | MSD | Ongoing | SITAGLIPTIN/ METFORMIN XR | 3 | MK0431A XR-289 | King Khalid University Hospital (Riyadh) |
| A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control | MSD | Ongoing | Sitagliptin | 3 | MK0431-083 | King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Hospital NG (Al Ahsa), Al-Noor Specialist Hospital (Makkah) |
| A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus Patients Intervention Study) | AstraZeneca | Ongoing | Ticagrelor | 3b | D513BC00001 | King Khalid University Hospital (Riyadh), King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Fahad University Hospital (Al-Khobar), Saud Al-Babtain Cardiac Center (Dammam) |
| A 52-week, double-blind, randomised, multi-centre, phase III, parallel-group study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' compared with Pulmicort (budesonide) Turbuhaler 200 μg twice daily plus terbutaline Turbuhaler 0.4 mg 'as needed' | AstraZeneca | Ongoing | Budesonide / Formoterol / Budesonide / Terbutaline | 3 | D589SC00003 | Armed Forces Hospital (Dhahran), King Fahad Specialist Hospital (Dammam), King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad University Hospital (Al-Khobar), King Faisal Specialist Hospital and Research Center (Jeddah) |
تاريخ آخر تحديث: 08/05/2025 بتمام الساعة 03:17 مساء بتوقيت المملكة العربية السعودية
لم يتم تقديم أي تقييمات لهذه الصفحة بعد.
التعليقات والاقتراحات
لأي استفسارات أو ملاحظات حول الخدمات الحكومية، يرجى تعبئة المعلومات المطلوبة.